PRQR (ProQR Therapeutics NV) YoY EBITDA Growth: 33.07% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRQR ProQR Therapeutics NV PRQR
50 GF Score
Price $2.13
GF Value $2.36
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV YoY EBITDA Growth?

ProQR Therapeutics NV PRQR -6.99% 50 YoY EBITDA Growth is 33.07% as of Jun. 2026. GuruFocus rates PRQR with a GF Score™ of 50/100 and a GF Value™ of $2.36 (Modestly Undervalued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. ProQR Therapeutics NV's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 33.07%.

ProQR Therapeutics NV's EBITDA per Share for the three months ended in Jun. 2026 was $-0.09.

ProQR Therapeutics NV YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV YoY EBITDA Growth Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.47 13.65 61.20 9.57 -46.08

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -234.21 -8.26 -13.11 -36.54 33.07
PRQR
50GF Score
ProQR Therapeutics NV PRQR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

ProQR Therapeutics NV's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.428--0.293)/ | -0.293 |
=-46.08 %

ProQR Therapeutics NV's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.085--0.127)/ | -0.127 |
=33.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 33.07% mean?
ProQR Therapeutics NV (PRQR) has a YoY EBITDA Growth of 33.07% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's YoY EBITDA Growth too high?
ProQR Therapeutics NV's current YoY EBITDA Growth is 33.07%. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's YoY EBITDA Growth compare to NWBO and IMRX?
ProQR Therapeutics NV's YoY EBITDA Growth of 33.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current YoY EBITDA Growth is 33.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, ProQR Therapeutics NV (PRQR) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.36, compared to a current price of $2.13 — trading 9.7% below its estimated fair value. The current YoY EBITDA Growth is 33.07%. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For ProQR Therapeutics NV (PRQR), the current YoY EBITDA Growth is 33.07% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (PRQR) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of $2.13 is trading 9.7% below its estimated GF Value™ of $2.36. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for PRQR:

  • YoY EBITDA Growth: 33.07%
  • GF Value™: $2.36 vs. price of $2.13 (9.7% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the PRQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges 0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for PRQR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price
$2.36
GF Value